Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old at the time of joining, with a life expectancy of at least 3 months.
• People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by laboratory testing of tissue or cell samples, and mainly of the type called adenocarcinoma.
• People whose cancer cannot be surgically removed and is at an advanced stage (Stage III or IV), based on scans such as CT, MRI, or PET-CT.
• People whose cancer has been assessed by the trial doctor as having the potential to become operable after treatment (confirm with trial site).
• People who have not previously received any cancer treatment, including chemotherapy, radiation therapy, targeted therapy, immunotherapy, or other systemic cancer medicines.
• People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale — meaning someone who is fully active, has some limitations but can care for themselves, or is up and about for more than half of waking hours.
• People whose blood test results within 14 days before joining show that their blood cell counts and bone marrow function are within acceptable levels, specifically: white blood cell count, neutrophil count, haemoglobin, and platelet count all meeting minimum thresholds (confirm exact values with trial site).
• People whose liver function tests within 14 days before joining are within acceptable ranges, with different thresholds depending on whether liver spread is present (confirm with trial site).
• People whose kidney function tests show creatinine levels within an acceptable range (confirm with trial site).
• Women who could become pregnant must have a negative pregnancy test within 7 days before joining, and must agree to use effective contraception during the study and for at least 12 weeks after the last dose.
• Male participants must either have had a surgical procedure making them unable to father children, or must agree to use effective contraception during the study and for at least 12 weeks after the last dose.
• People who are able to understand the study and are willing to sign a written consent form.
• People who are expected to be able to follow the study procedures and attend required follow-up visits.

Who may not be able to join:

• People whose cancer tests positive for a marker called HER2.
• People who have conditions that could significantly affect how oral medications are absorbed, such as difficulty swallowing, ongoing nausea or vomiting, long-term diarrhoea, or a bowel blockage.
• People with a known allergy or sensitivity to any of the study drugs — adebrelimab, apatinib, oxaliplatin, or S-1 — or to any of their ingredients.
• People who have had a severe allergic reaction to monoclonal antibody medicines in the past.
• People with an active autoimmune disease or immune condition that requires ongoing treatment with systemic medicines.
• People with an immune system condition present from birth or developed over time that causes immune deficiency.
• People who have used medicines that suppress the immune system within the 14 days before starting the study treatment.
• People who have received a live vaccine within 4 weeks before the first dose, or who plan to receive one during the study.
• People who have had a serious infection within 4 weeks before starting the study treatment.
• People who have previously received a transplanted organ or bone marrow/stem cells from another person.
• People with evidence of certain lung conditions, including lung scarring, lung inflammation, dust-related lung disease, radiation-related lung damage, drug-related lung damage, or significantly reduced lung function.
• People with high blood pressure that has not been controlled despite at least 3 months of blood pressure treatment.
• People with serious heart or blood vessel disease that is not under control.
• People assessed by the trial doctor as being at high risk of serious bleeding.
• People with significant nerve damage affecting the hands or feet, rated above Grade 2 on a standard medical scale (confirm with trial site).
• People who have taken part in another interventional clinical trial within 4 weeks before joining, or within a certain timeframe related to the previous trial's study drug — whichever is longer.
• People who, in the trial doctor's judgement, have any other condition that makes participation in the study unsuitable.

Important: Always verify eligibility with the trial site directly before applying.